Forecast

Buy	2
Hold	0
Sell	0

News Go to news feed

Edesa Biotech places public offering of about $25 million at $5.50 per share

Edesa Biotech announces a guaranteed public offering expected to raise approximately $25.0 million gross proceeds through the sale of common stock, associated warrants and pre-funded warrants. The combined offering is priced at $5.50 per common share plus warrant; pre-funded warrants are priced at $5.4999. The warrants have an exercise price of $7.50 and are immediately exercisable. There is a 30-day overallotment option for the underwriting banks, the closing is expected around August 21, 2026, and the proceeds are to be used for general corporate purposes as well as research & development and manufacturing. » More on de.investing.com
Edesa Biotech announces share offering — shares fall sharply in after-hours trading

Edesa Biotech has announced a guaranteed public offering of common shares or pre-funded warrants, together with accompanying warrants, after which the stock fell 15.2% in after-hours trading. The consortium is to be granted a 30-day option to purchase additional securities of up to 15% of the offering. Guggenheim Securities is sole bookrunner; the transaction is subject to market conditions and is expected to provide net proceeds for general corporate purposes, including working capital, research and manufacturing. » More on de.investing.com
Edesa Biotech starts public, syndicated stock offering

Edesa Biotech announced a public, syndicated offering of common stock or pre-funded warrants and accompanying warrants, with a syndicate option for up to 15% of the offering size. Guggenheim Securities is acting as sole book-running manager. Net proceeds are intended for general corporate purposes, including working capital and research, development and production. The offering is being made pursuant to an S-3 shelf registration and is subject to market conditions; final closing and terms are not guaranteed. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2010, Edesa Biotech has already paid 18,20€ in dividends. The last payout was in July 2010.

Financials

In the last quarter, Edesa Biotech had revenue of 0.00€ and net profit of −4.74m€

(EUR)	Jun 2026	YoY
Revenue	0.00	-
Gross profit	−22.47k	-
Net profit	−4.74m	219,23%
EBITDA	−4.84m	236,37%

Fundamentals

Metric	Value
Market capitalization	+36.79m€
Number of shares	9.63m
52-week high/low	+17,44€ - +0,62€
Dividends	No
Beta	1,08
P/E ratio	−2,63
PEG ratio	+0,09
P/B ratio	+4,55
P/S ratio	0,00

Company profile

Edesa Biotech, Inc. ist ein biopharmazeutisches Unternehmen, das sich mit dem Erwerb, der Entwicklung und der Vermarktung von Arzneimitteln im klinischen Stadium für entzündliche und immunologische Krankheiten beschäftigt, für die ein eindeutiger medizinischer Bedarf besteht. Die führenden Produktkandidaten sind EB05, ein monoklonaler Antikörper, der sich in einer klinischen Phase-3-Studie zur Behandlung des akuten Atemnotsyndroms bei Covid-19-Patienten befindet, und EB01, eine topische Behandlung, die sich in einer klinischen Phase-2B-Studie für chronische allergische Kontaktdermatitis befindet. Das Unternehmen hat eine Lizenzvereinbarung mit NovImmune SA zur Entwicklung monoklonaler Antikörper gegen TLR4 und CXCL10. Edesa Biotech, Inc. wurde 2015 gegründet und hat seinen Hauptsitz in Markham, Kanada.